ATL1102 CLINICAL TRIAL UPDATE

Melbourne, Australia – 2 April 2024: Percheron Therapeutics Limited, an international biotechnology company focused on the development of novel therapies for rare diseases, is pleased to provide an update on its ongoing international phase IIb clinical trial of ATL1102 in Duchenne muscular dystrophy.

Key Points

- As at 31 March 2024, 34 out of a total target of 45 patients have been randomised and have initiated treatment.
- An additional 7 patients are currently in screening or anticipated to shortly commence screening, and it is expected that the majority will be randomised in coming weeks.
- The company is working closely with sites to identify further patients, with an expectation that recruitment will be completed in the near future.
- To date, 9 patients have successfully transitioned into the open-label extension phase of the study, in which all patients receive ATL1102. No patients have withdrawn from the study. The adverse events seen in the study thus far are generally minor in severity and consistent with prior clinical experience.

"We continue to make steady progress with recruiting the study," commented Percheron CEO, Dr James Garner. "It is disappointing that we still have a few more patients to enroll, but our priority is naturally to ensure that all patients meet the strict eligibility criteria and that the study is conducted exactly in accordance with the protocol. At this stage, we continue to expect data in 2H CY2024, as previously indicated."

The company expects to provide further updates as the study moves towards full recruitment and as patients continue to transition into the open-label extension phase.

~ ENDS ~

About Percheron Therapeutics Limited

Percheron Therapeutics Limited [ASX: PER | US OTC: ATHJY | FSE: AWY] is a publicly listed biotechnology company focused on the development and commercialisation of novel therapies for rare diseases. The company's lead program is ATL1102, an antisense oligonucleotide targeting the CD49d receptor. ATL1102 is currently the subject of an ongoing international phase IIb clinical trial for the treatment of non-ambulant patients with Duchenne Muscular Dystrophy (DMD), for which data is expected in 2H CY2024. The company previously reported promising results from an exploratory phase IIa study of in the same population and has been awarded orphan drug designation (ODD) and rare pediatric disease designation (RPDD) by the US FDA.

For more information, please contact info@PercheronTx.com.

This announcement has been authorized for release to the Australian Securities Exchange by the Board of Directors.